SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle ...

Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia. Highlights from Woyach, professor in ...

Fewer Blood Clots With GLP-1 Rxs On tap at ASH this year: Presentations on improved therapies for ALL and CLL and reduced blood clots with weight loss drugs. Medscape Medical News, December 02 ...

Calquence has already wowed the American Society of Hematology (ASH) with some stunning data in CLL in combination ... leukaemia and Richter’s Transformation. Final data from a phase 1 study ...